Impact of Clinical and Pharmacological Parameters on Faecal Microbiota Transplantation Outcome in Clostridioides difficile Infections: Results of a 5‐Year French National Survey
Nicolas Benech,Nadim Cassir,Laurent Alric,Frédéric Barbut,Rui Batista,Alexandre Bleibtreu,Thomas Briot,Benjamin Davido,Tatiana Galperine,Anne‐Christine Joly,Nathalie Kapel,Chloé Melchior,Alexis Mosca,Biba Nebbad,Bénédicte Pigneur,Stéphane M. Schneider,Mathieu Wasiak,Julien Scanzi,Harry Sokol,the French Faecal Transplant Group (GFTF)
DOI: https://doi.org/10.1111/apt.18330
IF: 9.524
2024-10-11
Alimentary Pharmacology & Therapeutics
Abstract:Among 658 faecal microbiota transplantation (FMT) performed in 17 centres in France from 2018 to 2022 for Clostridioides difficile infection (CDI), severe chronic kidney disease, non‐severe refractory CDI, the use of ≥ 80% glycerol, insufficient bowel cleansing and partial FMT retention were associated with CDI recurrence within 8 weeks. Background Detailed comparative assessment of procedure‐related factors associated with faecal microbiota transplantation (FMT) efficacy in Clostridioides difficile infection (CDI) is limited. Aims We took advantage of the differences in procedures at the various French FMT centres to determine clinical and procedure‐related factors associated with FMT success in CDI. Methods We performed a nationwide retrospective multicentre cohort study. All FMTs performed within The French Faecal Transplant Group for CDI from 2018 to 2022 were included. Clinical data were collected retrospectively from recipient medical files, characteristics of stool transplant preparations were prospectively collected by each Pharmacy involved. Univariate and multivariate analyses were performed using Fisher's test and multiple logistic regression. Results Six hundred fifty‐eight FMTs were performed for 617 patients in 17 centres. The overall efficacy of FMT was 84.3% (520/617), with 0.5% of severe adverse events possibly related to FMT (3/658). Forty‐seven patients were treated at the first recurrence of CDI with a similar success rate (85.1%). Severe chronic kidney disease (CKD; OR: 2.18, 95%CI [1.20–3.88]), non‐severe refractory CDI (OR: 15.35, [1.94–318.2]), the use of ≥ 80% glycerol (OR: 2.52, [1.11–5.67]), insufficient bowel cleansing (OR: 5.47, [1.57–20.03]) and partial FMT retention (OR: 9.97, [2.62–48.49]) were associated with CDI recurrence within 8 weeks. Conclusions Conditions of transplant manufacturing, bowel cleansing, and a route of delivery tailored to the patient's characteristics are key factors in optimising FMT efficacy. FMT at first recurrence showed high success in real‐life practice, whereas it had lower efficacy in severe CDI and non‐severe refractory CDI.
pharmacology & pharmacy,gastroenterology & hepatology